ReviewWiener medizinische Wochenschrift (1946)2008
Cholestasis and metabolic bone disease - a clinical review.
Review in Wiener medizinische Wochenschrift (1946), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- ACG Clinical Guideline: Primary Sclerosing Cholangitis.The American journal of gastroenterology · 2015Guideline
- Hepatic osteodystrophy: An underrecognized metabolic bone disease.World journal of hepatology · 2025Review
- Osteoporosis Assessment among Adults with Liver Cirrhosis.Journal of clinical medicine · 2022Article
- A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis.Journal of clinical medicine · 2022Review
- The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis-a narrative review article.Annals of translational medicine · 2021Review
- Neonatal McCune-Albright Syndrome: A Unique Syndromic Profile With an Unfavorable Outcome.JBMR plus · 2019Article
- Hepatic Osteodystrophy-Molecular Mechanisms Proposed to Favor Its Development.International journal of molecular sciences · 2019Review
- A study on OPG/RANK/RANKL axis in osteoporotic bile duct-ligated rats and the involvement of nitrergic and opioidergic systems.Research in pharmaceutical sciences · 2018Article
- Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography.Medicine · 2018Article
- Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment.Clinics (Sao Paulo, Brazil) · 2017Article
- [Progress in diagnosis and therapy of extrahepatic manifestations of cholestatic liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Article
- Study of Hepatic Osteodystrophy in Patients with Chronic Liver Disease.Journal of clinical and diagnostic research : JCDR · 2016Article
- Diagnosis and Management of Cirrhosis-Related Osteoporosis.BioMed research international · 2016Review
- Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti-γ-Glutamyl Transpeptidase Antibody.PloS one · 2015Article
- Hepatic osteodystrophy.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases · 2014Review
- Increased bone mineral density in patients with non-alcoholic steatohepatitis.World journal of hepatology · 2013Article
- Article
- Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2012Article
- Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.World journal of hepatology · 2011Article
- Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats.Fibrogenesis & tissue repair · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic bone disease, mainly osteopenia/osteoporosis and occasionally osteomalacia, is a major extrahepatic manifestation of chronic cholestatic liver disease (synonym: hepatic osteodystrophy). Reduced bone mineral density is found in up to 60% and atraumatic fractures in about 20% of patients with chronic liver disease. Hepatic osteodystrophy is characterized by reduced formation and increased resorption of bone; major risk factors are chronic cholestasis and advanced cirrhosis. Pathogenetic mechanisms include genetic factors, abnormalities of calcium, vitamin D, vitamin K and bilirubin metabolism, IGF-1 deficiency, the RANKL/OPG-system, hypogonadism, drugs harmful to bone, lifestyle factors (smoking, alcoholism, immobility), malnutrition and low body mass index. Screening for osteopenia should be performed and reversible risk factors must be corrected. At present, bisphosphonates are the predominantly used specific drugs for the treatment of osteoporosis in chronic liver disease. After orthotopic liver transplantation bone mineral density improves in long-term follow-up. Studies are needed for fracture prevention in chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.